Loading…
Use of mPEG-PLGA nanoparticles to improve bioactivity and hemocompatibility of streptokinase: In-vitro and in-vivo studies
Streptokinase, a clot-dissolving agent, is widely used in treatment of cardiovascular diseases such as blood clots and deep thrombosis. Streptokinase is a cost-effective drug with a short biological half-life (i.e. 15 to 30 min). In addition, due to its prokaryotic source, the immune response quickl...
Saved in:
Published in: | Materials Science & Engineering C 2021-01, Vol.118, p.111427-111427, Article 111427 |
---|---|
Main Authors: | , , , |
Format: | Article |
Language: | English |
Subjects: | |
Citations: | Items that this one cites Items that cite this one |
Online Access: | Get full text |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
cited_by | cdi_FETCH-LOGICAL-c400t-131e209257b165c19b9e396a6896d7311b52bede3a8975bb88863f7becb509863 |
---|---|
cites | cdi_FETCH-LOGICAL-c400t-131e209257b165c19b9e396a6896d7311b52bede3a8975bb88863f7becb509863 |
container_end_page | 111427 |
container_issue | |
container_start_page | 111427 |
container_title | Materials Science & Engineering C |
container_volume | 118 |
creator | Hasanpour, Akram Esmaeili, Fariba Hosseini, Hossein Amani, Amir |
description | Streptokinase, a clot-dissolving agent, is widely used in treatment of cardiovascular diseases such as blood clots and deep thrombosis. Streptokinase is a cost-effective drug with a short biological half-life (i.e. 15 to 30 min). In addition, due to its prokaryotic source, the immune response quickly reacts to the drug. Despite these limitations, streptokinase is still the first choice for diseases associated with thrombosis. In this work, streptokinase was encapsulated in mPEG-PLGA nanoparticles to improve its pharmacokinetic properties. The nanoparticles containing the enzyme were prepared by coaxial electrospray and their physicochemical properties, blood compatibility, circulation time and cell toxicity were evaluated. The results showed that the use of mPEG-PLGA nanoparticles to encapsulate the enzyme resulted in prolonged circulation time (up to 120 min) with a slight decrease in its activity. In vivo studies also showed that the nanoparticles containing streptokinase did not have adverse effect on blood biochemistry parameters as well as liver and kidney tissues. As a result, the mPEG-PLGA nanoparticles showed the potential for increasing the biological activity of streptokinase with no important adverse effect.
[Display omitted]
•Coaxial electrospray was used to prepare nanoparticles of mPEG-PLGA/SK.•These NPs had an acceptable degree of blood compatibility and were not cytotoxic.•The NPs showed to be effective in increasing biological life time of the enzyme. |
doi_str_mv | 10.1016/j.msec.2020.111427 |
format | article |
fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2466036717</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0928493120333452</els_id><sourcerecordid>2466036717</sourcerecordid><originalsourceid>FETCH-LOGICAL-c400t-131e209257b165c19b9e396a6896d7311b52bede3a8975bb88863f7becb509863</originalsourceid><addsrcrecordid>eNp9kEtP3DAUha2qqAzQP9AF8rKbDH4kdoy6QQgGpJFgAWvLdu6oniZxsD0j0V9fh4EuWd2HvnOkcxD6QcmSEioutsshgVsywsqD0prJL2hBW8krQhX9ihZEsbaqFafH6CSlLSGi5ZJ9Q8ecs6YhrF6gv88JcNjg4fFmVT2uV1d4NGOYTMze9ZBwDtgPUwx7wNYH47Lf-_yKzdjh3zAEF4bJZG99P3-LT8oRphz--NEkuMT3Y1X4GN4Efj72oTC7zkM6Q0cb0yf4_j5P0fPtzdP1XbV-WN1fX60rVxOSK8opsJKkkZaKxlFlFXAljGiV6CSn1DbMQgfctEo21rZtK_hGWnC2Iarsp-jnwbfEeNlBynrwyUHfmxHCLmlWC0G4kFQWlB1QF0NKETZ6in4w8VVToufO9VbPneu5c33ovIjO3_13doDuv-Sj5AL8OgBQUu49RJ2ch9FB5yO4rLvgP_P_BzoCkyg</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2466036717</pqid></control><display><type>article</type><title>Use of mPEG-PLGA nanoparticles to improve bioactivity and hemocompatibility of streptokinase: In-vitro and in-vivo studies</title><source>ScienceDirect Freedom Collection</source><creator>Hasanpour, Akram ; Esmaeili, Fariba ; Hosseini, Hossein ; Amani, Amir</creator><creatorcontrib>Hasanpour, Akram ; Esmaeili, Fariba ; Hosseini, Hossein ; Amani, Amir</creatorcontrib><description>Streptokinase, a clot-dissolving agent, is widely used in treatment of cardiovascular diseases such as blood clots and deep thrombosis. Streptokinase is a cost-effective drug with a short biological half-life (i.e. 15 to 30 min). In addition, due to its prokaryotic source, the immune response quickly reacts to the drug. Despite these limitations, streptokinase is still the first choice for diseases associated with thrombosis. In this work, streptokinase was encapsulated in mPEG-PLGA nanoparticles to improve its pharmacokinetic properties. The nanoparticles containing the enzyme were prepared by coaxial electrospray and their physicochemical properties, blood compatibility, circulation time and cell toxicity were evaluated. The results showed that the use of mPEG-PLGA nanoparticles to encapsulate the enzyme resulted in prolonged circulation time (up to 120 min) with a slight decrease in its activity. In vivo studies also showed that the nanoparticles containing streptokinase did not have adverse effect on blood biochemistry parameters as well as liver and kidney tissues. As a result, the mPEG-PLGA nanoparticles showed the potential for increasing the biological activity of streptokinase with no important adverse effect.
[Display omitted]
•Coaxial electrospray was used to prepare nanoparticles of mPEG-PLGA/SK.•These NPs had an acceptable degree of blood compatibility and were not cytotoxic.•The NPs showed to be effective in increasing biological life time of the enzyme.</description><identifier>ISSN: 0928-4931</identifier><identifier>EISSN: 1873-0191</identifier><identifier>DOI: 10.1016/j.msec.2020.111427</identifier><identifier>PMID: 33255024</identifier><language>eng</language><publisher>Netherlands: Elsevier B.V</publisher><subject>Blood compatibility ; Coaxial electrospray ; Drug Carriers ; In vivo studies ; mPEG-PLGA nanoparticles ; Nanoparticles ; Particle Size ; Polyesters ; Polyethylene Glycols ; Streptokinase</subject><ispartof>Materials Science & Engineering C, 2021-01, Vol.118, p.111427-111427, Article 111427</ispartof><rights>2020 Elsevier B.V.</rights><rights>Copyright © 2020 Elsevier B.V. All rights reserved.</rights><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c400t-131e209257b165c19b9e396a6896d7311b52bede3a8975bb88863f7becb509863</citedby><cites>FETCH-LOGICAL-c400t-131e209257b165c19b9e396a6896d7311b52bede3a8975bb88863f7becb509863</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/33255024$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Hasanpour, Akram</creatorcontrib><creatorcontrib>Esmaeili, Fariba</creatorcontrib><creatorcontrib>Hosseini, Hossein</creatorcontrib><creatorcontrib>Amani, Amir</creatorcontrib><title>Use of mPEG-PLGA nanoparticles to improve bioactivity and hemocompatibility of streptokinase: In-vitro and in-vivo studies</title><title>Materials Science & Engineering C</title><addtitle>Mater Sci Eng C Mater Biol Appl</addtitle><description>Streptokinase, a clot-dissolving agent, is widely used in treatment of cardiovascular diseases such as blood clots and deep thrombosis. Streptokinase is a cost-effective drug with a short biological half-life (i.e. 15 to 30 min). In addition, due to its prokaryotic source, the immune response quickly reacts to the drug. Despite these limitations, streptokinase is still the first choice for diseases associated with thrombosis. In this work, streptokinase was encapsulated in mPEG-PLGA nanoparticles to improve its pharmacokinetic properties. The nanoparticles containing the enzyme were prepared by coaxial electrospray and their physicochemical properties, blood compatibility, circulation time and cell toxicity were evaluated. The results showed that the use of mPEG-PLGA nanoparticles to encapsulate the enzyme resulted in prolonged circulation time (up to 120 min) with a slight decrease in its activity. In vivo studies also showed that the nanoparticles containing streptokinase did not have adverse effect on blood biochemistry parameters as well as liver and kidney tissues. As a result, the mPEG-PLGA nanoparticles showed the potential for increasing the biological activity of streptokinase with no important adverse effect.
[Display omitted]
•Coaxial electrospray was used to prepare nanoparticles of mPEG-PLGA/SK.•These NPs had an acceptable degree of blood compatibility and were not cytotoxic.•The NPs showed to be effective in increasing biological life time of the enzyme.</description><subject>Blood compatibility</subject><subject>Coaxial electrospray</subject><subject>Drug Carriers</subject><subject>In vivo studies</subject><subject>mPEG-PLGA nanoparticles</subject><subject>Nanoparticles</subject><subject>Particle Size</subject><subject>Polyesters</subject><subject>Polyethylene Glycols</subject><subject>Streptokinase</subject><issn>0928-4931</issn><issn>1873-0191</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2021</creationdate><recordtype>article</recordtype><recordid>eNp9kEtP3DAUha2qqAzQP9AF8rKbDH4kdoy6QQgGpJFgAWvLdu6oniZxsD0j0V9fh4EuWd2HvnOkcxD6QcmSEioutsshgVsywsqD0prJL2hBW8krQhX9ihZEsbaqFafH6CSlLSGi5ZJ9Q8ecs6YhrF6gv88JcNjg4fFmVT2uV1d4NGOYTMze9ZBwDtgPUwx7wNYH47Lf-_yKzdjh3zAEF4bJZG99P3-LT8oRphz--NEkuMT3Y1X4GN4Efj72oTC7zkM6Q0cb0yf4_j5P0fPtzdP1XbV-WN1fX60rVxOSK8opsJKkkZaKxlFlFXAljGiV6CSn1DbMQgfctEo21rZtK_hGWnC2Iarsp-jnwbfEeNlBynrwyUHfmxHCLmlWC0G4kFQWlB1QF0NKETZ6in4w8VVToufO9VbPneu5c33ovIjO3_13doDuv-Sj5AL8OgBQUu49RJ2ch9FB5yO4rLvgP_P_BzoCkyg</recordid><startdate>202101</startdate><enddate>202101</enddate><creator>Hasanpour, Akram</creator><creator>Esmaeili, Fariba</creator><creator>Hosseini, Hossein</creator><creator>Amani, Amir</creator><general>Elsevier B.V</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>202101</creationdate><title>Use of mPEG-PLGA nanoparticles to improve bioactivity and hemocompatibility of streptokinase: In-vitro and in-vivo studies</title><author>Hasanpour, Akram ; Esmaeili, Fariba ; Hosseini, Hossein ; Amani, Amir</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c400t-131e209257b165c19b9e396a6896d7311b52bede3a8975bb88863f7becb509863</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2021</creationdate><topic>Blood compatibility</topic><topic>Coaxial electrospray</topic><topic>Drug Carriers</topic><topic>In vivo studies</topic><topic>mPEG-PLGA nanoparticles</topic><topic>Nanoparticles</topic><topic>Particle Size</topic><topic>Polyesters</topic><topic>Polyethylene Glycols</topic><topic>Streptokinase</topic><toplevel>online_resources</toplevel><creatorcontrib>Hasanpour, Akram</creatorcontrib><creatorcontrib>Esmaeili, Fariba</creatorcontrib><creatorcontrib>Hosseini, Hossein</creatorcontrib><creatorcontrib>Amani, Amir</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Materials Science & Engineering C</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Hasanpour, Akram</au><au>Esmaeili, Fariba</au><au>Hosseini, Hossein</au><au>Amani, Amir</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Use of mPEG-PLGA nanoparticles to improve bioactivity and hemocompatibility of streptokinase: In-vitro and in-vivo studies</atitle><jtitle>Materials Science & Engineering C</jtitle><addtitle>Mater Sci Eng C Mater Biol Appl</addtitle><date>2021-01</date><risdate>2021</risdate><volume>118</volume><spage>111427</spage><epage>111427</epage><pages>111427-111427</pages><artnum>111427</artnum><issn>0928-4931</issn><eissn>1873-0191</eissn><abstract>Streptokinase, a clot-dissolving agent, is widely used in treatment of cardiovascular diseases such as blood clots and deep thrombosis. Streptokinase is a cost-effective drug with a short biological half-life (i.e. 15 to 30 min). In addition, due to its prokaryotic source, the immune response quickly reacts to the drug. Despite these limitations, streptokinase is still the first choice for diseases associated with thrombosis. In this work, streptokinase was encapsulated in mPEG-PLGA nanoparticles to improve its pharmacokinetic properties. The nanoparticles containing the enzyme were prepared by coaxial electrospray and their physicochemical properties, blood compatibility, circulation time and cell toxicity were evaluated. The results showed that the use of mPEG-PLGA nanoparticles to encapsulate the enzyme resulted in prolonged circulation time (up to 120 min) with a slight decrease in its activity. In vivo studies also showed that the nanoparticles containing streptokinase did not have adverse effect on blood biochemistry parameters as well as liver and kidney tissues. As a result, the mPEG-PLGA nanoparticles showed the potential for increasing the biological activity of streptokinase with no important adverse effect.
[Display omitted]
•Coaxial electrospray was used to prepare nanoparticles of mPEG-PLGA/SK.•These NPs had an acceptable degree of blood compatibility and were not cytotoxic.•The NPs showed to be effective in increasing biological life time of the enzyme.</abstract><cop>Netherlands</cop><pub>Elsevier B.V</pub><pmid>33255024</pmid><doi>10.1016/j.msec.2020.111427</doi><tpages>1</tpages><oa>free_for_read</oa></addata></record> |
fulltext | fulltext |
identifier | ISSN: 0928-4931 |
ispartof | Materials Science & Engineering C, 2021-01, Vol.118, p.111427-111427, Article 111427 |
issn | 0928-4931 1873-0191 |
language | eng |
recordid | cdi_proquest_miscellaneous_2466036717 |
source | ScienceDirect Freedom Collection |
subjects | Blood compatibility Coaxial electrospray Drug Carriers In vivo studies mPEG-PLGA nanoparticles Nanoparticles Particle Size Polyesters Polyethylene Glycols Streptokinase |
title | Use of mPEG-PLGA nanoparticles to improve bioactivity and hemocompatibility of streptokinase: In-vitro and in-vivo studies |
url | http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-24T17%3A50%3A15IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Use%20of%20mPEG-PLGA%20nanoparticles%20to%20improve%20bioactivity%20and%20hemocompatibility%20of%20streptokinase:%20In-vitro%20and%20in-vivo%20studies&rft.jtitle=Materials%20Science%20&%20Engineering%20C&rft.au=Hasanpour,%20Akram&rft.date=2021-01&rft.volume=118&rft.spage=111427&rft.epage=111427&rft.pages=111427-111427&rft.artnum=111427&rft.issn=0928-4931&rft.eissn=1873-0191&rft_id=info:doi/10.1016/j.msec.2020.111427&rft_dat=%3Cproquest_cross%3E2466036717%3C/proquest_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c400t-131e209257b165c19b9e396a6896d7311b52bede3a8975bb88863f7becb509863%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=2466036717&rft_id=info:pmid/33255024&rfr_iscdi=true |